Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer

This study has been completed.
Sponsor:
Collaborator:
OSI Pharmaceuticals
Information provided by (Responsible Party):
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
NCT00046800
First received: October 3, 2002
Last updated: October 18, 2011
Last verified: October 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2003
  Estimated Primary Completion Date: No date given